HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ashour, H. M. Articles by Niederkorn, J. Y. Search for Related Content PubMed PubMed Citation Articles by Ashour, H. M. Articles by Niederkorn, J. Y.

T Cells Promote Anterior Chamber-Associated Immune Deviation and Immune Privilege through Their Production of IL-10¹

Hossam M. Ashour^* and Jerry Y. Niederkorn^2,

^* Immunology Graduate Program and Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Anterior chamber-associated immune deviation (ACAID) is a form of peripheral tolerance that is induced by introducing Ags into the anterior chamber (AC) of the eye, and is maintained by Ag-specific regulatory T cells (Tregs). ACAID regulates harmful immune responses that can lead to irreparable injury to innocent bystander cells that are incapable of regeneration. This form of immune privilege in the eye is mediated through Tregs and is a product of complex cellular interactions. These involve F4/80⁺ ocular APCs, B cells, NKT cells, CD4⁺CD25⁺ Tregs, and CD8⁺ Tregs. T cells are crucial for the generation of ACAID and for corneal allograft survival. However, the functions of T cells in ACAID are unknown. Several hypotheses were proposed for determining the functions of T cells in ACAID. The results indicate that T cells do not cause direct suppression of delayed-type hypersensitivity nor do they act as tolerogenic APCs. In contrast, T cells were shown to secrete IL-10 and facilitate the generation of ACAID Tregs. Moreover, the contribution of T cells ACAID generation could be replaced by adding exogenous recombinant mouse IL-10 to ACAID spleen cell cultures lacking T cells.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Anterior chamber-associated immune deviation (ACAID)³ is a form of peripheral tolerance that is induced by introducing Ags into the anterior chamber (AC) of the eye and is maintained by Ag-specific regulatory T cells (Tregs) (1, 2). ACAID is characterized by an Ag-specific down-regulation of delayed-type hypersensitivity (DTH) responses. Down-regulation of DTH is a common feature of immune privileged sites and is believed to be a protective mechanism against immune-mediated inflammatory damage of the nonregenerating cells in the eye, brain, and allogeneic fetus (3). Thus, Tregs generated in ACAID are crucial for the maintenance of immune privilege of the eye (1).

The generation of Tregs after the introduction of the Ag into the AC is a product of complex cellular interactions. The process involves F4/80⁺ ocular APCs, which initially capture and process the Ag in the predominantly immunosuppressive environment of the aqueous humor (1, 2). The F4/80⁺ ocular APCs then migrate to the thymus and spleen where they interact with other cells leading to the generation of CD4⁺CD25⁺ Tregs and CD8⁺ Tregs (4, 5, 6). Whereas CD4⁺CD25⁺ Tregs block the induction or afferent component of the immune response, CD8⁺ Tregs inhibit the expression of DTH by previously sensitized T cells (i.e., the efferent component of the immune response). Studies have shown that the Ag released by F4/80⁺ ocular APCs is captured via the BCR on the splenic B cells (7). B cells then internalize the Ag, process it, and present it to CD4⁺ T cells in the context of MHC class II (MHC-II) and to CD8⁺ T cells in the context of MHC-I (7, 8, 9). Thus, B cells act as ancillary APCs that are crucial for generation of Tregs in ACAID (7, 8).

Although the vast majority of T cells express a TCR composed of heterodimers, there is a small proportion of T cells that expresses a heterodimer TCR. These T cells are typically CD4^–/CD8^– (10). However, CD8⁺ T cells and CD4⁺ T cells have been reported (11, 12). T cells are required for the generation of ACAID and for corneal graft survival (13, 14, 15). In addition, T cells have been shown to play a role in other forms of tolerance, including oral tolerance (16, 17, 18, 19, 20), testicular tolerance (21, 22), nasal tolerance (11, 23), and tumor-associated tolerance (22, 24, 25). Moreover, T cells contribute to the immune privilege of allogeneic fetuses during pregnancy (26, 27).

Taking all this into consideration, we proposed several hypotheses for determining the functions of T cells in ACAID. The results indicate that T cells do not cause direct suppression of DTH nor do they act as tolerogenic APCs. However, T cells were shown to secrete IL-10 and facilitate the generation of ACAID Tregs.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Animals

C57BL/6 (H-2^b) mice; B6.129P2-2m^tm1Unc/J (₂-microglobulin knockout (KO) or class I-deficient) mice; -chain KO mice (TCRKO) (C57BL/ 6J-Tcrd^tm1Mom), IL-4 KO mice (B6.129P2-Il4^tm1Cgn/J), IFN- KO mice (B6-IFN-^tm1Ts/J), and IL-10 KO mice (B6.129P2-IL-10^tm1Cgn/J) were purchased from The Jackson Laboratory. B6.129-H2-Ab1^tm1Gru N12 (MHC-II-deficient) mice were purchased from Taconic Farms. All animals were housed and cared for in accordance with the guidelines of the University Committee for the Humane Care of Laboratory Animals, the National Institutes of Health Guidelines on Laboratory Animal Welfare, and the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.

Antibodies

GL3 Ab was produced from hybridoma cells and purified by protein A columns and was graciously provided by Dr. L. Lefrancois (University of Connecticut, Farmington, CT). This Ab inhibits the function of T cells by blocking the TCR -chain (18). Animals were treated i.p. with 500 µg of GL3 Ab on days –3, +4, and +11. This in vivo depletion protocol was slightly modified from Skelsey et al. (14). In other experiments, T cells were depleted in vitro using purified anti-mouse TCR (UC7-13D5; BD Biosciences) plus complement (Cedarlane Laboratories). CD8 T cells were depleted in vitro using purified rat anti-mouse CD8a (Ly-2; BD Biosciences) plus complement (Cedarlane Laboratories). The Ab isotype controls used were hamster IgG3 for the UC-7 and rat IgG2a for the Ly-2 (BD Biosciences). PE-conjugated anti-mouse TCR (GL3) Ab (BD Biosciences) was used to specifically label T cells from within the B cell-depleted spleen cell population of normal C57BL/6 mice and different types of KO mice (IL-10 KO mice, IL-4 KO mice, and IFN- KO mice) before sorting of the T cell population using the flow cytometric facility at University of Texas Southwestern Medical Center.

Subcutaneous immunization

Mice were immunized by s.c. injection of 250 µg of OVA (Sigma-Aldrich) in PBS and emulsified 1/1 in CFA (Sigma-Aldrich). Each mouse received a 200-µl total volume.

AC injection

A Hamilton automatic dispensing apparatus was used to inject 100 µg (in 5 µl) of OVA into the AC as described previously (7, 14).

DTH assay

An ear swelling assay was used to measure DTH to OVA as described previously (6, 14). Results were expressed as: specific ear swelling = (24-h measurement – 0-h measurement) for experimental ear – (24-h measurement – 0-h measurement) for negative control ear.

Generation of ACAID-like APCs

ACAID-like APCs were generated in vitro using a previously described protocol that has been used extensively for analyzing Tregs in ACAID (5, 8, 28, 29, 30, 31, 32). Peritoneal exudate cells were collected from C57BL/6 mice and cultured overnight (2 x 10⁶ cells per ml) in complete RPMI 1640 medium supplemented with 10 mg/ml OVA and 2 ng/ml human TGF-2 (R&D Systems). These ACAID-like APCs induce peripheral tolerance that is identical with ACAID (4, 5, 7).

Generation of ACAID B cells

An in vitro culture system was used to generate B cells that are capable of inducing the generation of Tregs that express the same phenotype as those induced by AC injection of the Ag (4, 28, 33). OVA-pulsed ACAID-like APCs generated in vitro as described above were cocultured for 48 h with B cells isolated from the spleens of normal C57BL/6 mice using CD45R (B220) microbeads (Miltenyi Biotec). These ACAID-inducing B cells were then adoptively transferred into either normal C57BL/6 mice or T cell KO mice (4 x 10⁶ B cells per mouse). The viability of B cells was determined by trypan blue exclusion immediately before the adoptive transfer and was always >95%.

In vitro ACAID model of Treg cell generation

We used an in vitro spleen cell culture system that generates Tregs that express the same properties and surface markers as Tregs produced by AC injection (4, 5, 6, 7, 9, 34). These in vitro-generated Tregs are Ag-specific CD8⁺ T cells that can directly inhibit DTH (7).

ACAID-like APCs (5 x 10⁶) were added to a large petri dish (Falcon 3003; BD Biosciences) containing 5 x 10⁷ spleen cells harvested from either normal C57BL/6 mice or T cell KO mice. Spleen cell cultures were incubated for 5–7 days at 37°C before being tested for the presence of Tregs. Viability of the in vitro-generated Tregs was always >95% as assessed by trypan blue exclusion.

In some experiments, two spleen equivalents of T cells (sorted from spleen cells of C57BL/6 mice, MHC-I KO mice, or MHC-II KO) were used to reconstitute spleen cell cultures from T cell KO mice. In our hands, the yield of T cells from two spleens ranged from 5 x 10⁵ to 10⁶ T cells. One group of the reconstituting T cells was treated with chloroquine (80 µM/2 x 10⁵ cells) (Sigma-Aldrich), checked for viability by trypan blue exclusion, and then added to reconstitute the in vitro spleen cell cultures. In other groups, 10 ng/ml of either recombinant mouse (rm) IL-10 (R&D Systems) or rmIL-4 (R&D Systems) was added to the culture medium.

Local adoptive transfer (LAT) assay

This assay was used to test for Tregs in ACAID (7, 9). Putative Tregs were injected (1 x 10⁶ cells in 10 µl) with spleen cells (1 x 10⁶ cells in 10 µl) collected from s.c. immunized donors and 10 mg/ml OVA into the left ear pinna of a naive mouse. The presence of Tregs was demonstrated by the suppression of the ear swelling responses mediated by immune spleen cells.

Statistics

Statistical significance of DTH was determined using Student’s t test.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
T cells are necessary for the induction of ACAID

ACAID is a sequential process that is contingent on the presence of multiple cell populations in the spleen (3, 35). Among these, the Ag-presenting B cell population and T cell population are both crucial for ACAID generation (7, 14). To determine the role of T cells in the induction of ACAID, it was important to determine whether they acted upstream or downstream of B cells following AC injection of the Ag. The initial steps in the induction of ACAID can be recapitulated in vitro by coculturing Ag-pulsed, ACAID-like APCs with spleen cells from normal mice. After 5–7 days of in vitro culture, CD8⁺ Tregs are generated that have the same properties of Tregs induced by AC injection of the Ag. To determine whether T cells acted downstream from B cells in the induction of ACAID, we tested the capacity of ACAID-inducing B cells to generate ACAID in mice deficient in T cells. ACAID-inducing B cells were generated in vitro by coculturing OVA-pulsed, ACAID-like APCs with purified B cells suspensions for 2 days. B cells generated in such cultures will induce ACAID when adoptively transferred to naive mice (7, 8, 34). Accordingly, ACAID B cells were adoptively transferred into either T cell KO mice or wild-type C57BL/6 mice depleted of T cells using anti- T cell Ab. The recipients of adoptively transferred B cells were immunized s.c. with OVA plus CFA and subsequently tested for OVA-specific DTH. The results indicated that, as expected, recipients of ACAID-inducing B cells demonstrated impaired DTH responses to OVA, even though these mice had been immunized s.c. with OVA plus CFA (Fig. 1). By contrast, both categories of T cell-deficient mice did not display evidence of suppressed DTH and developed ear swelling responses comparable to that of positive control mice. These results suggest that T cells act downstream from B cells during the induction of ACAID.

View larger version (14K): [in this window] [in a new window]   FIGURE 1. ACAID B cells cannot induce ACAID in KO mice or T cell-depleted mice. A, ACAID B cells were generated in vitro, injected IV (4 x 106 cells per mouse) into KO mice or wild-type C57BL/6 (B6) mice. Mice were then immunized s.c. with OVA plus CFA 7 days later. DTH responses to OVA were assessed 7 days after s.c. immunization using an ear swelling assay. B, ACAID B cells were generated in vitro, injected i.v. (4 x 106 cells per mouse) into either T cell-depleted B6 mice or normal B6 mice. Mice were then immunized s.c. with OVA plus CFA 7 days later. DTH responses to OVA were assessed 7 days after s.c. immunization using an ear swelling assay.

T cells do not act as ACAID Tregs

The splenic phase of ACAID involves the interactions between ocular APCs, B cells, NKT cells, CD4⁺ T cells, CD8⁺ T cells, and T cells. Because T cells act downstream from ACAID B cells, it is possible that T cells are, in fact, the end-stage Tregs that suppress the expression of DTH. To test this hypothesis, ACAID Tregs were generated in vitro and spleen cell cultures were depleted of T cells immediately before testing for Treg cell activity in a LAT assay. Previous studies have demonstrated that ACAID Tregs are CD8⁺ (36). Therefore, as a control, the in vitro generated Tregs were treated with anti-CD8 Ab plus complement to remove Treg activity. The results indicated that, as expected, removal of CD8⁺ T cells abolished Treg activity and allowed full expression of OVA-specific DTH (Fig. 2) By contrast, depletion of T cells did not remove Treg activity and indicated that T cells do not act as the end-stage Tregs in ACAID. The use of isotype controls for each of the depleting Abs did not interfere with the generation of Tregs as expected.

View larger version (17K): [in this window] [in a new window]   FIGURE 2. T cells do not mediate efferent suppression of DTH. ACAID-like APCs were generated in vitro, incubated with spleen cells for 5–7 days to generate ACAID Tregs. T cells were treated with purified anti-mouse TCR (or isotype control Ab) plus complement. Tregs were also treated with purified rat anti-mouse CD8a (or isotype control Ab) plus complement. A LAT assay was performed using OVA plus OVA-immune spleen cells. *, p < 0.01, compared with all other groups except positive control.

T cells do not function as APCs in the induction of ACAID

It has been demonstrated recently that T cells can act as APCs (37, 38). ACAID culminates in the generation of MHC-II-restricted CD4⁺ Tregs and MHC-I-restricted CD8⁺ Tregs and thus requires APCs that present Ag on MHC-I and MHC-II molecules (8). If T cells act as APCs for the induction of ACAID, then reconstituting T cell KO mice with T cells from either MHC-I- or MHC-II-deficient donors should not restore ACAID in T cell KO recipients. This hypothesis was tested by reconstituting T cell KO mice with 5 x 10⁵ T cells from wild-type C57BL/6 mice, MHC-I-deficient mice, or MHC-II-deficient mice. One week after reconstitution, OVA was injected into the AC of reconstituted T cell KO mice and control mice. Seven days later, mice were immunized s.c. with OVA emulsified in CFA. OVA-specific DTH was assessed 7 days after the s.c. immunization. As anticipated, nonreconstituted T cell KO mice failed to develop ACAID (Fig. 3A). However, reconstitution with T cells restored the capacity of T cell KO mice to develop ACAID. Importantly, reconstitution with T cells from either MHC-I- or MHC-II-deficient donors successfully restored ACAID, indicating that T cells did not act as APCs for the induction of ACAID.

View larger version (12K): [in this window] [in a new window]   FIGURE 3. T cells do not play an Ag presentation role in ACAID. A, T cell KO mice were reconstituted with 5 x 105 T cells from MHC-I KO mice, MHC-II KO mice, or wild-type mice. OVA was injected into the AC 7 days after T cell reconstitution. Mice were immunized s.c. with OVA plus CFA 7 days after the AC injections with OVA. DTH responses to OVA were assessed 7 days after the s.c. immunization using an ear swelling assay. *, p < 0.01, compared with each of the three groups of T cell reconstituted mice. B, Absence of T cells precludes the generation of Tregs in vitro. ACAID-like APCs from B6 mice were generated in vitro, incubated (5 x 106) with spleen cells (5 x 107) from either B6 mice or T cell KO mice. After 5–7 days, the spleen cell suspensions were tested in a LAT assay for their capacity to suppress DTH responses to OVA. C, ACAID-like APCs were generated in vitro, incubated (5 x 106) with spleen cells (5 x 107) from T cell KO mice without or with T cells from B6 mice, MHC-II KO mice, or MHC-I KO mice. Another group was incubated with chloroquine-treated T cells from B6 mice. After 5–7 days, the spleen cell suspensions were tested in a LAT assay for their capacity to suppress DTH responses to OVA. *, p < 0.01, compared with positive control.

Moreover, chloroquine treatment prevents Ag presentation and the induction of ACAID by F4/80⁺ ACAID-like APCs and by splenic B cells (7, 39). Therefore, T cells were subjected to a similar chloroquine treatment protocol to determine whether T cells did not act as APCs in the induction of ACAID. T cells isolated from wild-type C57BL/6 mice were either untreated or treated with chloroquine before being used to reconstitute spleen cell cultures prepared from T cell KO mice. T cells from either MHC-I KO or MHC-II KO mice were used to reconstitute similar spleen cell cultures. Spleen cell cultures were used to generate ACAID Tregs as before. Following 5 days in culture, Treg activity was examined in the previously described LAT assay. The results indicated that neither chloroquine treatment nor deficiencies in MHC-I or MHC-II expression prevented T cells from restoring ACAID in the spleen cell cultures prepared from T cell KO mice (Fig. 3C) and thus provided further evidence that T cells did not function as APCs in the induction of ACAID.

T cells must produce IL-10 to induce ACAID

Studies have shown that T cells have the capacity to produce a variety of cytokines, including IL-10, IL-4, and IFN (40, 41, 42, 43, 44). Other reports have suggested that the immunosuppressive function of T cells is mediated mainly by cytokines (42, 45). Because ACAID is a Th2-like phenomenon with an immunosuppressive consequence, we hypothesized that T cells need to secrete Th2 cytokines (such as IL-10 and IL-4) for the generation of efferent Tregs and down-regulation of DTH. Although IFN- is a signature cytokine for Th1 cells, it is also necessary for the generation of Tregs in some models and is known to mitigate some Th1-immune-mediated diseases (46). The possibility that production of IL-4, IL-10, or IFN- by T cells was involved in the induction of ACAID was explored.

T cell KO mice were reconstituted with 5 x 10⁵ T cells from IFN- KO mice, IL-4 KO mice, or IL-10 KO mice. One week after reconstitution, OVA was injected into the AC of reconstituted T cell KO mice and control mice. Seven days later, mice were immunized s.c. with OVA emulsified in CFA. OVA-specific DTH was assessed 7 days after the s.c. immunization. The lack of either IFN- or IL-4 did not affect the ability of T cells to reconstitute the generation of ACAID (Fig. 4). However, T cells from IL-10 KO donors were incapable of restoring ACAID in T cell KO mice and indicated that production of this cytokine was crucial for the T cell’s contribution to the induction of ACAID (Fig. 4).

View larger version (12K): [in this window] [in a new window]   FIGURE 4. T cells do not need to secrete IFN- or IL-4 but do need to secrete IL-10 for the generation of ACAID. A, T cell KO mice were reconstituted with spleen equivalents of T cells from wild-type or IFN- KO mice. OVA was injected into the AC 7 days after T cell reconstitution. Mice were then immunized s.c. with OVA plus CFA 7 days later. DTH responses to OVA were assessed 7 days after s.c. immunization using an ear swelling assay. B, T cell KO mice were reconstituted with spleen equivalents of T cells from wild-type or IL-4 KO mice. OVA was injected into the AC 7 days after T cell reconstitution. Mice were then immunized s.c. with OVA plus CFA 7 days later. DTH responses to OVA were assessed 7 days after s.c. immunization using an ear swelling assay. C, T cell KO mice were reconstituted with spleen equivalents of T cells from wild-type or IL-10 KO mice. OVA was injected into the AC 7 days after T cell reconstitution. Mice were then immunized s.c. with OVA plus CFA 7 days later. DTH responses to OVA were assessed 7 days after s.c. immunization using an ear swelling assay.

View larger version (16K): [in this window] [in a new window]   FIGURE 5. The rmIL-10 can fully replace the function of T cells in ACAID. ACAID-like APCs were generated in vitro, incubated (5 x 106) with spleen cells (5 x 107) from T cell KO mice with or without T cells from B6 mice. One group contained rmIL-10 (10 ng/ml) but no T cells. Another group contained rmIL-4 (10 ng/ml) but no T cells. A control group contained rmIL-10 and spleen cells from KO mice but no APCs. After 5–7 days, the spleen cell suspensions were tested in a LAT assay for their capacity to suppress DTH responses to OVA. *, p < 0.01.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Peripheral tolerance that is induced when Ag enters an immune privileged site, such as the eye, regulates harmful immune responses that can lead to irreparable injury to innocent bystander cells that are incapable of regeneration. Corneal endothelial cells and cells forming the retina are examples of terminally differentiated ocular cells that cannot undergo mitosis and regenerate. Injury to either of these cell populations can lead to blindness. Whether ACAID prevents the generation or the expression of autoimmune Th1 immune responses in the eye under normal physiological conditions remains to be established. However, it is noteworthy that inducing ACAID by AC injection of either retinal-specific autoantigens or corneal alloantigens results in the mitigation of experimental autoimmune uveitits and the acceptance of cornal allografts, respectively (47, 48, 49).

The induction of ACAID involves a complex series of events and the participation of at least four organs (eye, thymus, spleen, and sympathetic nervous system) and at least six different cell populations (ocular APCs (3), B cells (7, 8), T cells (14, 45, 50), NKT cells (32, 51), CD4⁺ T cells (5, 6), and CD8⁺ T cells (36)). After capturing Ag in the AC, F4/80⁺ ocular APCs migrate to the thymus (33) and spleen (52). In the spleen, the F4/80⁺ ocular APCs interact with NKT cells, CD4⁺ T cells, and B cells (51, 53). Recent evidence suggests that splenic B cells capture antigenic peptides released by the F4/80⁺ ocular APCs and present these Ags to both CD4⁺ and CD8⁺ T cells, leading to the generation of efferent-acting Tregs (8). Where T cells function in the induction of ACAID remains to be identified.

There are several strategic points in the induction of ACAID where T cells might function. The recent report that T cells can function as APCs (37) led us to test the hypothesis that T cells act as ancillary APCs in the induction of ACAID. However, two findings argue against this role. First, chloroquine treatment inhibits the Ag-presenting function of T cells (37) yet does not affect the capacity of T cells to contribute to the generation of ACAID. The induction of ACAID requires simultaneous presentation of Ags on both MHC-I and MHC-II molecules (8), yet the present findings indicate that T cells from mice deficient in the expression of either MHC-I or MHC-II molecules were still capable of contributing to the induction of ACAID.

The results reported in this study indicate that the T cell acts downstream from the ACAID B cell, as adoptive transfer of ACAID B cells into T cell KO mice fails to induce ACAID. We considered the obvious explanation that T cells acted as efferent Treg cells that inhibited the expression of DTH, as T cells are known to secrete immunosuppressive and anti-inflammatory molecules (45). Moreover, some T cell populations express the CD8 molecule, which is also found on ACAID efferent Tregs (11). However, our findings demonstrate that removal of T cells from ACAID CD8⁺ Treg suspensions does not abolish CD8⁺ T cell-mediated suppression of DTH, thereby confirming that T cells do not function as ACAID efferent Tregs.

We are attracted to the hypothesis that T cells act as ancillary producers of IL-10, which is known to be crucial for the induction of ACAID (54). This proposition is supported by the finding that T cells from wild-type mice, IL-4 KO mice, or IFN- KO mice can restore ACAID in T cell KO mice, while T cells from IL-10 KO donors cannot. Moreover, the contribution of T cells in the induction of ACAID could be replaced by simply adding exogenous rmIL-10 cytokine to ACAID spleen cell cultures lacking T cells. These results fit well with data showing a cytokine secretion function for T cells in other systems (40, 41, 42, 43, 44, 45, 55). These results are also in accordance with data from tumor models showing a critical regulatory role for IL-10 production through T cells in inhibiting immune elimination of tumors (24, 56).

Many unanswered questions remain that pertain to the role of T cells in ACAID. The segregation of T cells into functionally specialized cell populations in correlation with TCR variable gene expression (57), raises an interesting yet challenging question. This question is to determine which of these subpopulations of T cells is particularly involved in ACAID and what kind of interaction it has with other T cells and other cells. Because T cells were shown to interact with cells of the innate system at many levels (57), unraveling these interactions in the immunoregulatory setting of ACAID is also important. Finally, the details of the Ag recognition process by T cells in ACAID need to be thoroughly investigated.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grants EY005631 and EY016664 and an unrestricted grant from Research to Prevent Blindness, New York, NY.

² Address correspondence and reprint requests to Dr. Jerry Y. Niederkorn, Department of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390. E-mail address: jerry.niederkorn{at}utsouthwestern.edu

³ Abbreviations used in this paper used: ACAID, anterior chamber-associated immune deviation; AC, anterior chamber; Treg, T regulatory cell; DTH, delayed-type hypersensitivity; MHC-II, MHC class II; KO, knockout; rm recombinant mouse; LAT, local adoptive transfer assay.

Received for publication July 13, 2006. Accepted for publication September 29, 2006.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Niederkorn, J. Y.. 2002. Immune privilege in the anterior chamber of the eye. Crit. Rev. Immunol. 22: 13-46. [Medline]
2. Streilein, J. W.. 2003. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3: 879-889. [Medline]
3. Niederkorn, J. Y.. 2006. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 7: 354-359. [Medline]
4. Sonoda, K. H., J. Stein-Streilein. 2002. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur. J. Immunol. 32: 848-857. [Medline]
5. Lin, H. H., D. E. Faunce, M. Stacey, A. Terajewicz, T. Nakamura, J. Zhang-Hoover, M. Kerley, M. L. Mucenski, S. Gordon, J. Stein-Streilein. 2005. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J. Exp. Med. 201: 1615-1625. [Abstract/Free Full Text]
6. Skelsey, M. E., E. Mayhew, J. Y. Niederkorn. 2003. CD25⁺, interleukin-10-producing CD4⁺ T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology 110: 18-29. [Medline]
7. Skelsey, M. E., E. Mayhew, J. Y. Niederkorn. 2003. Splenic B cells act as antigen presenting cells for the induction of anterior chamber-associated immune deviation. Invest. Ophthalmol. Vis. Sci. 44: 5242-5251. [Abstract/Free Full Text]
8. Ashour, H. M., J. Y. Niederkorn. 2006. Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation. J. Immunol. 176: 5950-5957. [Abstract/Free Full Text]
9. D’Orazio, T. J., E. Mayhew, J. Y. Niederkorn. 2001. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J. Immunol. 166: 26-32. [Abstract/Free Full Text]
10. Guidos, C.. 2006. Thymus and T-lymphocyte development: what is new in the 21st century?. Immunol. Rev. 209: 5-9. [Medline]
11. Harrison, L. C., M. Dempsey-Collier, D. R. Kramer, K. Takahashi. 1996. Aerosol insulin induces regulatory CD8 T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 184: 2167-2174. [Abstract/Free Full Text]
12. Lusso, P., A. Garzino-Demo, R. W. Crowley, M. S. Malnati. 1995. Infection of T lymphocytes by human herpesvirus 6: transcriptional induction of CD4 and susceptibility to HIV infection. J. Exp. Med. 181: 1303-1310. [Abstract/Free Full Text]
13. Xu, Y., J. A. Kapp. 2002. T cells in anterior chamber-induced tolerance in CD8⁺ CTL responses. Invest. Ophthalmol. Vis. Sci. 43: 3473-3479. [Abstract/Free Full Text]
14. Skelsey, M. E., J. Mellon, J. Y. Niederkorn. 2001. T cells are needed for ocular immune privilege and corneal graft survival. J. Immunol. 166: 4327-4333. [Abstract/Free Full Text]
15. Xu, Y., J. A. Kapp. 2001. T cells are critical for the induction of anterior chamber-associated immune deviation. Immunology 104: 142-148. [Medline]
16. Wildner, G., T. Hunig, S. R. Thurau. 1996. Orally induced, peptide-specific TCR⁺ cells suppress experimental autoimmune uveitis. Eur. J. Immunol. 26: 2140-2148. [Medline]
17. Mengel, J., F. Cardillo, L. S. Aroeira, O. Williams, M. Russo, N. M. Vaz. 1995. Anti- T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Immunol. Lett. 48: 97-102. [Medline]
18. Ke, Y., K. Pearce, J. P. Lake, H. K. Ziegler, J. A. Kapp. 1997. T lymphocytes regulate the induction and maintenance of oral tolerance. J. Immunol. 158: 3610-3618. [Abstract]
19. Ke, Y., J. A. Kapp. 1996. Oral antigen inhibits priming of CD8⁺ CTL, CD4⁺ T cells, and antibody responses while activating CD8⁺ suppressor T cells. J. Immunol. 156: 916-921. [Abstract]
20. Okunuki, H., R. Teshima, Y. Sato, R. Nakamura, H. Akiyama, T. Maitani, J. Sawada. 2005. The hyperresponsiveness of W/Wv mice to oral sensitization is associated with a decrease in TCR-T cells. Biol. Pharm. Bull. 28: 584-590. [Medline]
21. Mukasa, A., K. Hiromatsu, G. Matsuzaki, R. O’Brien, W. Born, K. Nomoto. 1995. Bacterial infection of the testis leading to autoaggressive immunity triggers apparently opposed responses of and T cells. J. Immunol. 155: 2047-2056. [Abstract]
22. Seo, N., K. Egawa. 1995. Suppression of cytotoxic T lymphocyte activity by T cells in tumor-bearing mice. Cancer Immunol. Immunother. 40: 358-366. [Medline]
23. McMenamin, C., M. McKersey, P. Kuhnlein, T. Hunig, P. G. Holt. 1995. T cells down-regulate primary IgE responses in rats to inhaled soluble protein antigens. J. Immunol. 154: 4390-4394. [Abstract]
24. Seo, N., Y. Tokura, M. Takigawa, K. Egawa. 1999. Depletion of IL-10- and TGF--producing regulatory T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163: 242-249. [Abstract/Free Full Text]
25. Seo, N., Y. Tokura, F. Furukawa, M. Takigawa. 1998. Down-regulation of tumoricidal NK and NKT cell activities by MHC Kb molecules expressed on Th2-type T and T cells coinfiltrating in early B16 melanoma lesions. J. Immunol. 161: 4138-4145. [Abstract/Free Full Text]
26. Heyborne, K. D., R. L. Cranfill, S. R. Carding, W. K. Born, R. L. O’Brien. 1992. Characterization of T lymphocytes at the maternal-fetal interface. J. Immunol. 149: 2872-2878. [Abstract]
27. Suzuki, T., K. Hiromatsu, Y. Ando, T. Okamoto, Y. Tomoda, Y. Yoshikai. 1995. Regulatory role of T cells in uterine intraepithelial lymphocytes in maternal antifetal immune response. J. Immunol. 154: 4476-4484. [Abstract]
28. Mathis, D., C. Benoist. 2004. Back to central tolerance. Immunity 20: 509-516. [Medline]
29. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor -chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164. [Abstract]
30. Wenkel, H., J. W. Streilein, M. J. Young. 2000. Systemic immune deviation in the brain that does not depend on the integrity of the blood-brain barrier. J. Immunol. 164: 5125-5131. [Abstract/Free Full Text]
31. Sonoda, K. H., M. Exley, S. Snapper, S. P. Balk, J. Stein-Streilein. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190: 1215-1226. [Abstract/Free Full Text]
32. Sonoda, K. H., D. E. Faunce, M. Taniguchi, M. Exley, S. Balk, J. Stein-Streilein. 2001. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J. Immunol. 166: 42-50. [Abstract/Free Full Text]
33. Wang, Y., I. Goldschneider, J. O’Rourke, R. E. Cone. 2001. Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J. Leukocyte Biol. 69: 741-746. [Abstract/Free Full Text]
34. D’Orazio, T. J., J. Y. Niederkorn. 1998. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology 95: 47-55. [Medline]
35. Niederkorn, J. Y.. 2003. Mechanisms of immune privilege in the eye and hair follicle. J. Investig. Dermatol. Symp. Proc. 8: 168-172. [Medline]
36. Wilbanks, G. A., J. W. Streilein. 1990. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen: evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology 71: 383-389. [Medline]
37. Brandes, M., K. Willimann, B. Moser. 2005. Professional antigen-presentation function by human T cells. Science 309: 264-268. [Abstract/Free Full Text]
38. Moser, B., M. Brandes. 2006. T cells: an alternative type of professional APC. Trends Immunol. 27: 112-118. [Medline]
39. Hara, Y., R. R. Caspi, B. Wiggert, M. Dorf, J. W. Streilein. 1992. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J. Immunol. 149: 1531-1538. [Abstract]
40. Wen, L., D. F. Barber, W. Pao, F. S. Wong, M. J. Owen, A. Hayday. 1998. Primary cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation. J. Immunol. 160: 1965-1974. [Abstract/Free Full Text]
41. Ferrick, D. A., M. D. Schrenzel, T. Mulvania, B. Hsieh, W. G. Ferlin, H. Lepper. 1995. Differential production of interferon- and interleukin-4 in response to Th1- and Th2-stimulating pathogens by T cells in vivo. Nature 373: 255-257. [Medline]
42. Seo, N., Y. Tokura. 1999. Down-regulation of innate and acquired antitumor immunity by bystander and T lymphocytes with Th2 or Tr1 cytokine profiles. J. Interferon Cytokine Res. 19: 555-561. [Medline]
43. Ebert, L. M., S. Meuter, B. Moser. 2006. Homing and function of human skin T cells and NK cells: relevance for tumor surveillance. J. Immunol. 176: 4331-4336. [Abstract/Free Full Text]
44. Wang, T., E. Scully, Z. Yin, J. H. Kim, S. Wang, J. Yan, M. Mamula, J. F. Anderson, J. Craft, E. Fikrig. 2003. IFN--producing T cells help control murine West Nile virus infection. J. Immunol. 171: 2524-2531. [Abstract/Free Full Text]
45. Kapp, J. A., L. M. Kapp, K. C. McKenna, J. P. Lake. 2004. T-cell clones from intestinal intraepithelial lymphocytes inhibit development of CTL responses ex vivo. Immunology 111: 155-164. [Medline]
46. Wood, K. J., B. Sawitzki. 2006. Interferon-: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 27: 183-187. [Medline]
47. Niederkorn, J. Y., J. Mellon. 1996. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 37: 2700-2707. [Abstract/Free Full Text]
48. Sonoda, Y., J. W. Streilein. 1993. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J. Immunol. 150: 1727-1734. [Abstract]
49. Mizuno, K., A. F. Clark, J. W. Streilein. 1989. Anterior chamber-associated immune deviation induced by soluble antigens. Invest. Ophthalmol. Vis. Sci. 30: 1112-1119. [Abstract/Free Full Text]
50. McKenna, K. C., Y. Xu, J. A. Kapp. 2002. Injection of soluble antigen into the anterior chamber of the eye induces expansion and functional unresponsiveness of antigen-specific CD8⁺ T cells. J. Immunol. 169: 5630-5637. [Abstract/Free Full Text]
51. Faunce, D. E., K. H. Sonoda, J. Stein-Streilein. 2001. MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol. 166: 313-321. [Abstract/Free Full Text]
52. Wilbanks, G. A., J. W. Streilein. 1992. Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties. Reg. Immunol. 4: 130-137. [Medline]
53. Faunce, D. E., J. Stein-Streilein. 2002. NKT cell-derived RANTES recruits APCs and CD8⁺ T cells to the spleen during the generation of regulatory T cells in tolerance. J. Immunol. 169: 31-38. [Abstract/Free Full Text]
54. D’Orazio, T. J., J. Y. Niederkorn. 1998. A novel role for TGF- and IL-10 in the induction of immune privilege. J. Immunol. 160: 2089-2098. [Abstract/Free Full Text]
55. Holtmeier, W., D. Kabelitz. 2005. T cells link innate and adaptive immune responses. Chem. Immunol. Allergy 86: 151-183. [Medline]
56. Ke, Y., L. M. Kapp, J. A. Kapp. 2003. Inhibition of tumor rejection by T cells and IL-10. Cell. Immunol. 221: 107-114. [Medline]
57. Born, W. K., C. L. Reardon, R. L. O’Brien. 2006. The function of T cells in innate immunity. Curr. Opin. Immunol. 18: 31-38. [Medline]

This article has been cited by other articles:

				S. Chattopadhyay, J. O'Rourke, and R. E. Cone Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells Int. Immunol., April 1, 2008; 20(4): 509 - 516. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ashour, H. M. Articles by Niederkorn, J. Y. Search for Related Content PubMed PubMed Citation Articles by Ashour, H. M. Articles by Niederkorn, J. Y.